These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 15507431)

  • 1. A novel mode of Gleevec binding is revealed by the structure of spleen tyrosine kinase.
    Atwell S; Adams JM; Badger J; Buchanan MD; Feil IK; Froning KJ; Gao X; Hendle J; Keegan K; Leon BC; Müller-Dieckmann HJ; Nienaber VL; Noland BW; Post K; Rajashankar KR; Ramos A; Russell M; Burley SK; Buchanan SG
    J Biol Chem; 2004 Dec; 279(53):55827-32. PubMed ID: 15507431
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biochemical properties of the Cdc42-associated tyrosine kinase ACK1. Substrate specificity, authphosphorylation, and interaction with Hck.
    Yokoyama N; Miller WT
    J Biol Chem; 2003 Nov; 278(48):47713-23. PubMed ID: 14506255
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571).
    Nagar B; Bornmann WG; Pellicena P; Schindler T; Veach DR; Miller WT; Clarkson B; Kuriyan J
    Cancer Res; 2002 Aug; 62(15):4236-43. PubMed ID: 12154025
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular basis for a direct interaction between the Syk protein-tyrosine kinase and phosphoinositide 3-kinase.
    Moon KD; Post CB; Durden DL; Zhou Q; De P; Harrison ML; Geahlen RL
    J Biol Chem; 2005 Jan; 280(2):1543-51. PubMed ID: 15536084
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structural basis for the autoinhibition of c-Abl tyrosine kinase.
    Nagar B; Hantschel O; Young MA; Scheffzek K; Veach D; Bornmann W; Clarkson B; Superti-Furga G; Kuriyan J
    Cell; 2003 Mar; 112(6):859-71. PubMed ID: 12654251
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Abl family kinases regulate FcγR-mediated phagocytosis in murine macrophages.
    Greuber EK; Pendergast AM
    J Immunol; 2012 Dec; 189(11):5382-92. PubMed ID: 23100514
    [TBL] [Abstract][Full Text] [Related]  

  • 7. STI-571: an anticancer protein-tyrosine kinase inhibitor.
    Roskoski R
    Biochem Biophys Res Commun; 2003 Oct; 309(4):709-17. PubMed ID: 13679030
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Equally potent inhibition of c-Src and Abl by compounds that recognize inactive kinase conformations.
    Seeliger MA; Ranjitkar P; Kasap C; Shan Y; Shaw DE; Shah NP; Kuriyan J; Maly DJ
    Cancer Res; 2009 Mar; 69(6):2384-92. PubMed ID: 19276351
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structural mechanism for STI-571 inhibition of abelson tyrosine kinase.
    Schindler T; Bornmann W; Pellicena P; Miller WT; Clarkson B; Kuriyan J
    Science; 2000 Sep; 289(5486):1938-42. PubMed ID: 10988075
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Solution structure of the C-terminal SH2 domain of the human tyrosine kinase Syk complexed with a phosphotyrosine pentapeptide.
    Narula SS; Yuan RW; Adams SE; Green OM; Green J; Philips TB; Zydowsky LD; Botfield MC; Hatada M; Laird ER
    Structure; 1995 Oct; 3(10):1061-73. PubMed ID: 8590001
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of Tyr518 and Tyr519 in the regulation of catalytic activity and substrate phosphorylation by Syk protein-tyrosine kinase.
    Couture C; Williams S; Gauthier N; Tailor P; Mustelin T
    Eur J Biochem; 1997 Jun; 246(2):447-51. PubMed ID: 9208937
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Conformation-selective inhibitors reveal differences in the activation and phosphate-binding loops of the tyrosine kinases Abl and Src.
    Hari SB; Perera BG; Ranjitkar P; Seeliger MA; Maly DJ
    ACS Chem Biol; 2013 Dec; 8(12):2734-43. PubMed ID: 24106839
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of wild-type and mutant Bcr-Abl by AP23464, a potent ATP-based oncogenic protein kinase inhibitor: implications for CML.
    O'Hare T; Pollock R; Stoffregen EP; Keats JA; Abdullah OM; Moseson EM; Rivera VM; Tang H; Metcalf CA; Bohacek RS; Wang Y; Sundaramoorthi R; Shakespeare WC; Dalgarno D; Clackson T; Sawyer TK; Deininger MW; Druker BJ
    Blood; 2004 Oct; 104(8):2532-9. PubMed ID: 15256422
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Explaining why Gleevec is a specific and potent inhibitor of Abl kinase.
    Lin YL; Meng Y; Jiang W; Roux B
    Proc Natl Acad Sci U S A; 2013 Jan; 110(5):1664-9. PubMed ID: 23319661
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Computational analysis of the binding specificity of Gleevec to Abl, c-Kit, Lck, and c-Src tyrosine kinases.
    Lin YL; Roux B
    J Am Chem Soc; 2013 Oct; 135(39):14741-53. PubMed ID: 24001034
    [TBL] [Abstract][Full Text] [Related]  

  • 16. c-Abl tyrosine kinase and inhibition by the cancer drug imatinib (Gleevec/STI-571).
    Nagar B
    J Nutr; 2007 Jun; 137(6 Suppl 1):1518S-1523S; discussion 1548S. PubMed ID: 17513418
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Syk interacts with tyrosine-phosphorylated proteins in human platelets activated by collagen and cross-linking of the Fc gamma-IIA receptor.
    Yanaga F; Poole A; Asselin J; Blake R; Schieven GL; Clark EA; Law CL; Watson SP
    Biochem J; 1995 Oct; 311 ( Pt 2)(Pt 2):471-8. PubMed ID: 7487883
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structural and biophysical characterization of the Syk activation switch.
    Grädler U; Schwarz D; Dresing V; Musil D; Bomke J; Frech M; Greiner H; Jäkel S; Rysiok T; Müller-Pompalla D; Wegener A
    J Mol Biol; 2013 Jan; 425(2):309-33. PubMed ID: 23154170
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mutations in the activation loop tyrosines of protein tyrosine kinase Syk abrogate intracellular signaling but not kinase activity.
    Zhang J; Kimura T; Siraganian RP
    J Immunol; 1998 Oct; 161(8):4366-74. PubMed ID: 9780214
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Deregulated Syk inhibits differentiation and induces growth factor-independent proliferation of pre-B cells.
    Wossning T; Herzog S; Köhler F; Meixlsperger S; Kulathu Y; Mittler G; Abe A; Fuchs U; Borkhardt A; Jumaa H
    J Exp Med; 2006 Dec; 203(13):2829-40. PubMed ID: 17130299
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.